

Supplementary Materials




Figure S1: prevalence of ex-novo triad findings occurrence in our cohort of antisynthetase syndrome patients according to follow-up length (established range: 0–60 months)




Figure S2: prevalence in percentage of ongoing and previous treatments of the included cohort of antisynthetase patients. Treatments have been included as a whole, by considering that our results confirmed the substantial homogeneity of the syndrome.

Table 1. Cox proportional hazard model for estimating the time of ex-novo occurrence of triad findings.

	HR	95%CI	P
ARS			
Anti-Jo-1	1		
Anti-PL-7	0.83	0.60-1.13	0.24
Anti-PL-12	0.42	0.28-0.65	<0.001
Anti-EJ ARS	0.54	0.22-1.30	0.17
Anti-OJ	1.09	0.70-1.72	0.69
Sex (Male vs Female)	0.82	0.65-1.05	0.11
Age at onset (years)	1	0.99-1.01	0.26
Follow-up group (months)			
0-12	1		
13-24	0.48	0.29-0.80	0.005
25-60	0.51	0.35-0.76	0.001
>60	0.28	0.19-0.41	<0.001

hazard ratio (HR), 95% confidence interval (95% CI) and *p*-value (P) for each predictor are reported. Statistically significant differences ($p < 0.05$) in bold. Legend: ARS, antisynthetase antibodies